ArticleInternational journal of hematology2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Article in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.Cancer medicine · 2018Trial
- Trial
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Leukemia · 2015Trial
- Is there a best frontline therapy in chronic myeloid leukemia?Haematologica · 2026Review
- Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients.Pharmaceutics · 2024Article
- Accelerated-phase CML: de novo and transformed.Hematology. American Society of Hematology. Education Program · 2023Article
- Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.Pharmaceutics · 2022Article
- Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study.JMIR medical informatics · 2022Article
- Imatinib can act as an Allosteric Activator of Abl Kinase.Journal of molecular biology · 2022Article
- Current status and novel strategy of CML.International journal of hematology · 2021Review
- Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor for Patients with Chronic Myeloid Leukemia.Cancer management and research · 2021Article
- [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments.Frontiers in bioengineering and biotechnology · 2020Article
- Early Management of CML.Current hematologic malignancy reports · 2019Review
- Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.British journal of clinical pharmacology · 2019Review
- Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.Blood advances · 2019Article
- Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.Leukemia · 2016Review
- Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.Seminars in oncology · 2015Review
- Cardiotoxicity of anticancer treatments.Nature reviews. Cardiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 % for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 %; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival(PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR.Adverse events were more frequent with high-dose imatinib. Patients with B1 treatment interruption (vs [1) and those able to maintain imatinib C600 mg/day (vs\600 mg/day) in the first year of treatment had faster and higher response rates, but no improvement in EFS or PFS. Adherence to prescribed dose without interruption may be more important than initiation of therapy with higher doses of imatinib. Achievement of MMR correlated with longterm clinical outcomes.
Indexed as
Identifiers
24658916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.